- MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344
- MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients
- MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum
- MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia
- MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.26 |
---|---|
High | 3.26 |
Low | 3.20 |
Bid | 3.20 |
Offer | 3.27 |
Previous close | 3.26 |
Average volume | 13.16k |
---|---|
Shares outstanding | 6.66m |
Free float | 6.63m |
P/E (TTM) | 1.09 |
Market cap | 21.72m USD |
EPS (TTM) | 2.98 USD |
Data delayed at least 15 minutes, as of Apr 25 2024 16:31 BST.
More ▼